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Summary. Bacterial vaginoses are frequent in women, most of them involving Gardnerella vaginalis. In more than 50% of 
the cases, usual antibiotic treatments are not capable of eliminating completely the infection, leading to recurrent vaginosis. In 
addition to the appearance of antibiotic resistance, recurrence can be due to the development of a biofilm by G. vaginalis. In 
vitro experiments on G. vaginalis biofilms showed that the biofilm protected bacteria from the antibiotic clindamycin. Also, 
recombinant human lysozyme (rhLys) was able to both degrade biofilms and prevent their formation. This degradation effect 
persisted whenever other vaginal commensal or pathogenic microorganisms were added to the culture and on each tested 
clinical biofilm-producing strain of G. vaginalis. The co-administration of rhLys and clindamycin or metronidazole improved 
both antibiotics’ efficiency and lysozyme-driven biofilm degradation. The comparison of both clindamycin and metronidazole 
antibacterial spectra showed that metronidazole was preferable to treat vaginosis. This suggests that human lysozyme could be 
added as an anti-biofilm cotreatment to vaginal antibiotherapy, preferably metronidazole, against Gardnerella vaginalis 
infection in vivo. [Int Microbiol 19(2): 101-107 (2016)]
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It has been estimated that more than women 300 million around 
the world suffer from urogenital infections, including bladder, 
kidney, vagina, urethra, periurethra, and cervix infections 
[15,18]. During vaginal infections, the commensal saprophytic 
vaginal microbiota is replaced by a pathogenic microbiota [14]. 
Bacterial vaginoses are frequent [12] and most of them involve, 
or could even be triggered by, Gardnerella vaginalis [19], a 
bacterium capable to produce a biofilm. The usual treatment 
is antibiotherapy, mainly with clindamycin or metronidazole 
[2]. However, after antibiotic treatment, more than 30% of the 
patients suffer from recurrent infections after 3–6 months (and 
more than 50% after 12 months) [5]. This is due, probably, 
to the inability of antibiotics to efficiently reach bacteria 
embedded inside the biofilm. Biofilms have indeed been shown 
to be able to trap antibiotics on their matrix components [3,16], 
reducing their availability inside the biofilm and thus their 
efficiency. This can be one of the mechanisms causing antibiotic 
resistance. In addition, bacteria growing inside biofilms can 
be in a quiescent state, less sensitive to antibiotic treatment 
[11]. After the treatment, residual living bacteria can therefore 
grow again and originate a new infection burst. Additionally, 
antibiotherapy might also kill all the pathogenic bacteria inside 
the biofilm, leaving intact the biofilm matrix, which could serve 
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as a nest for new pathogens. Enzymatic targeting of biofilms 
by lysozyme has been reported to degrade biofilms produced 
by certain bacterial species [10,20], but could have opposite 
effects on other biofilms [21]. In the present work, we analyzed 
the use of recombinant human lysozyme as a potential G. 
vaginalis biofilm-degrading treatment in co-administration 
with antibiotics (clindamycin or metronidazole) in order to 
reduce the amount of biofilm biomass and to improve antibiotic 
efficiency.
Material and methods
Strains, culture conditions and biofilm formation. The 
following bacterial strains were purchased from the BCCM/LMG Bacteria 
Collection (Gent, Belgium): Lactobacillus crispatus (LMG12005), 
Lactobacillus gasseri (LMG13134), Lactobacillus jensenii (LMG6414), 
Lactobacillus iners (LMG18913), Gardnerella vaginalis (LMG14333 
and LMG7832), Prevotella bivia (LMG6452), Bacteroides vulgatus 
(LMG17767), Peptostreptococcus tetradius (LMG14264) and Escherichia 
coli (LMG2092). The Candida albicans strain was purchased from the 
ATCC (ATCC10231). Prof. Pierrette Melin, from the Medical Microbiology 
Laboratory, University Hospital of Liege, Belgium, provided us with 9 
clinical strains of G. vaginalis isolated from vaginal samples and coded Gv 1 
to Gv 9. Lactobacillus species are commensal, other species are pathogenic.
The cells were maintained on Schaedler agar enriched with vitamin 
K1 and 5% sheep blood (BioMerieux, Brussels, Belgium) at 37 °C under 
anaerobic conditions. Biofilms were grown at 37 °C under anaerobic 
atmosphere in 96-well plates in 100 ml Schaedler broth enriched with 
vitamin K3 (BioMerieux) for colony forming units (CFU) counting and for 
biofilm quantification. Ring-Test strips in 100 ml BHI (BioMerieux) were 
used for Ring-Test assay to evaluate the ability of strains to form biofilms. 
E-test Clindamycin (BioMerieux) was used to test antimicrobial resistance 
according to the manufacturer’s instructions.
Antibiotics and lysozyme. The following antibiotics and lysozyme 
tested in this work were purchased from Sigma-Aldrich (Belgium): 
clindamycin hydrochloride (C5269), metronidazole (M1547), and recom-
binant human lysozyme (rhLys) produced in rice (L1667). This lysozyme 
was selected in an attempt to reduce as much as possible the human immune 
response [1,17].
Toxicity test on eukaryotic cells (MTS assay). The toxicity of 
rhLys, clindamycin and metronidazole was tested on the VK2/E6E7 cell line, 
representative of the vaginal epithelium and obtained from its creator, Prof. 
Raina Fichorova (Boston, MA, USA) [7]. A total of 20,000 cells in 100 ml per 
well were cultured in 96-well plates in keratinocyte serum-free medium (Ker-
SFM, Life Technologies, Gent, Belgium) as previously described [7]. After 24 h, 
the culture medium was replaced (100 ml/well) by antibiotics and lysozyme 
dissolved in culture medium or by fresh culture medium alone (negative 
control). Toxicity was assessed 24 h later using the 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
(MTS) assay (Promega, Brussels, Belgium) according to the manufacturer’s 
instructions.
Biofilm quantification, biofilm immobilization assay and 
cellular viability of biofilm bacteria. The quantification biofilm 
formation was performed by using the crystal violet staining assay. Biofilms 
were fixed in 100 ml pure methanol for 15 min and then were stained in 100 
ml 0.1% crystal violet solution (Merck, Belgium) for another 15 min. Excess 
stain was removed with water. Staining was solubilized from biofilms in 
100 ml 33% acetic acid and the absorbance of the liquid was measured at 
595 nm wavelength using an Epoch microplate spectrophotometer (BioTek 
Instruments, Winooski, VT, USA).
Biofilm immobilization assay from BioFilm Control (Saint Beauzire, 
France), providing data about biofilm cohesion, has been previously 
described [6]. Additionally, the strips were here coated at 37 °C with 100 
ml 3% bovine serum albumin (BSA) in phosphate buffer saline (PBS) for 
1 h, and then rinsed. Biofilms were generated as described above, in the 
presence of the kit magnetic beads. Antibiotics and lysozyme or negative 
control (culture broth alone) were added (10 ml/well) when required without 
replacing the broth, and the beads displacement was tested according to the 
manufacturer’s instructions. The counting of viable bacteria from biofilms 
was performed by counting colony forming units (CFU). Biofilms were 
generated as described above, then scraped off and resuspended in 200 ml of 
fresh medium. Suspensions were then plated on Schaedler agar enriched with 
vitamin K1 and 5% sheep blood (Becton Dickinson, Belgium) and incubated 
at 37°C under anaerobic atmosphere for 48 h before CFU counting.
Statistical tests. Statistical analyses were performed on toxicity tests, 
biofilm immobilization assays and biofilm quantification assays results using 
2-way ANOVA followed by Bonferroni’s post-test.
Results
Toxicity test on eukaryotic cells (MTS assay). 
The results of the assessment of potential toxicity of 
clindamycin, metronidazole and rhLys on the VK2/E6E7 cell 
line, as a model for the vaginal epithelium, are shown in Fig. 
1. The maximal concentrations of the tested antibiotics and 
lysozyme were selected based respectively on their solubility 
and on the literature [21]. No detectable toxicity was observed 
in the presence of metronidazole (tested up to 600 mg/ml), 
lysozyme (tested up to 100,000 U/ml) or clindamycin up to 
200 mg/ml. However, the cell activity was significantly lower 
in the presence of clindamycin 400 and 600 mg/ml. Upper 
concentrations limits for this study were as follows: 100 mg/
ml for clindamycin (200 mg/ml was considered to be too close 
to toxic levels), 600 mg/ml for metronidazole, and 100,000 U/
ml for lysozyme. 
Protection provided to Gardnerella vaginalis by 
its biofilm (E-Test and CFU counting). Protection 
against antibiotic provided to bacteria present in the vaginal 
biofilm was illustrated on G. vaginalis (LMG14333) using 
clindamycin. Using an E-Test, the minimum inhibitory 
concentration (MIC) of clindamycin for that strain was 0.064 
mg/ml. We arbitrarily multiplied that concentration by a 1000-
fold factor (64 mg/ml) and applied it on a 24 h G. vaginalis 
biofilm for another 24 h. CFU counting was then performed 
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on bacteria present in the supernatant or included inside the 
biofilm. Results showed 100% mortality for the cells present 
in the supernatant while 0.66% of the cells present in the 
biofilm survived the treatment, when compared to antibiotic-
free control.
Anti-biofilm activity of rhLys (biofilm immo-
bilization assay and crystal violet staining). 
Recombinant human lysozyme rhLys was added (100,000 U/
ml) to G. vaginalis (LMG7832) cells before biofilm formation 
or to 24-h biofilm to check its anti-biofilm activity. Results 
showed that this lysozyme rhLys could both prevent biofilm 
formation and degrade existing biofilm (Fig. 2).  
A pathological vaginal biofilm contains multiple species. 
Biofilms were generated by a 50:50 mix of G. vaginalis 
(LMG14333) and each of the following vaginal species: 
L. crispatus, L. gasseri, L. jensenii, L. iners, Prev. bivia, B. 
vulgatus, E. coli, Pept. tetradius and C. albicans. Recombinant 
human lysozyme rhLys 100,000 U/ml was added on 24-h 
biofilms and biofilm were quantitated 24 h later. Figure 3 
shows the differences in the degradation of biofilms of the 
nine species tested. 
The anti-biofilm activity of rhLys 100,000 U/ml was 
then tested for 24 h on 24-h biofilms produced by 9 clinical 
strains of G. vaginalis. The lysozyme significantly reduced 
the biomass of 8 out of the 9 biofilms tested (Fig. 4), with 
great differences among strains. Strain Gv 4 produced very 
little biofilm compared to the other tested strains and its 
biomass reduction by this lysozyme did not reach statistical 
significance. Biomass reduction in our test conditions ranged 
from 20% to 95%, with a mean of 59% for these 9 strains. 
Impact of rhLys on antibiotic efficiency (CFU 
counting and biofilm immobilization assay). The 
impact of rhLys on antibiotic efficiency against G. vaginalis 
biofilm was first tested with clindamycin. Gardnerella 
vaginalis (LMG14333) biofilms were generated during 24 h. 
Various concentrations of clindamycin (0.5, 1, 2, 4, 8, 16, 32 
Fig. 1. Cellular activity (MTS assay) of vk2/E6E7 cells 
after 24 h in the presence of (A) dilutions of clindamycin 
(CL) or metronidazole (Me) (2 h MTS contact), or (B) 
rhLys (Ly) (1 h MTS contact). NA: no antibiotic. NL: 
no lysozyme. Statistically significant differences from 
control without antibiotic are represented as follows: **: 
P < 0.01; ***: P < 0.001; n = 3. I
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and 64 µg/ml) were then added during 24 h with or without 
lysozyme 20,000 U/ml.
Adding rhLys to clindamycin from 4µg/ml and above 
reduced the number of remaining CFUs obtained after biofilm 
homogenization by factors ranging from 4.1-fold to 8.6-fold, 
providing a more efficient treatment against G. vaginalis 
biofilm than clindamycin used alone.
Clindamycin and metronidazole can both be used to 
treat vaginoses. In order to check which antibiotic had the 
most suitable range of activity against vaginal species, each 
antibiotic was added to 72 h biofilm generated by each of 
the following species: L. crispatus, L. gasseri, L. jensenii, 
L. iners, G. vaginalis (LMG14333), Prev. bivia, B. vulgatus, 
Pept. tetradius and E. coli.
Table 1 shows first that, at their highest tested concen-
tration, clindamycin killed 100% of the cells of 2 out of 4 
pathogenic species, while metronidazole achieved 100% mor-
tality in each of these species. Also, clindamycin (100 mg/ml) 
killed 100% of the cells of each of the tested commensal 
species. Some L. crispatus and L. gasseri cells remained alive 
and were capable of proliferation after metronidazole 600 
mg/ml treatment. L. iners and B. vulgatus did not survive the 
96h culture and produced no CFU. They were not included in 
Table 1. The yeast C. albicans has not been tested here.
Considering the interest of selecting metronidazole to 
kill vaginal pathogenic bacteria in biofilms (Table 1), rhLys 
(100,000 U/ml) was added to metronidazole (600 mg/ml) 
on a 72 h G. vaginalis (LMG7832) biofilm and their impact 
on biofilm degradation was tested after 24 h using a biofilm 
immobilization assay. Metronidazole-only and lysozyme-only 
conditions were added in comparison. Metronidazole-only 
condition did not show any biofilm degradation (72 h biofilm 
BFI [BioFilm Index]: 1.45; BFI after 24 h of metronidazole: 
1.50). A low BFI means a mechanically resistant biofilm able 
to block the kit magnetic beads. As expected, the lysozyme-
only condition weakened the biofilm (BFI rising up to 7.97). 
However, lysozyme and metronidazole co-administration 
degraded the biofilm even more, with a BFI reaching 10.59. 
These differences were statistically significant (P < 0.001). 
Fig. 3. Anti-biofilm activity (crystal violet 
staining) of rhLys 100,000 U/ml added on 
24 h biofilms produced by a 50:50 mixes of 
Gardnerella vaginalis and each of 9 other 
vaginal species. Statistically significant 
differences between conditions with and 
without lysozyme are represented as 
follows: ***: P < 0.001; n = 3.
Int Microbiol
Fig. 2. Anti-biofilm activity (biofilm immobilization assay) of rhLys 100,000 
U/ml added before biofilm formation or on a 24-h biofilm produced by 
Gardnerella vaginalis. Lower BioFilm Index (BFI) means stronger biofilm. 
Statistically significant differences between conditions with and without 
rhLys at start for each time point are represented as follows: °°°: P < 0.001, 
while differences from 24 h without lysozyme at start are represented as 
follows: **: P < 0.01; ***: P < 0.001; n = 3.
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Discussion
Nowadays, it is admitted that biofilms can act as a protective 
shielding for bacteria [4,13]. This can occur following 
several mechanisms, such as trapping antibiotics before they 
can reach their target [16] or keeping bacteria in quiescent 
state in some parts of the biofilm [9]. We found that biofilms 
produced by G. vaginalis were able to protect the bacteria 
against clindamycin, an antibiotic frequently used to treat 
vaginoses, allowing a fraction of the cells to survive an 
antibiotic administration equal to 1000× the MIC. In vivo, 
this phenomenon could trigger recurrent vaginoses. Highly 
recurrent vaginoses could be due to bacteria forming very 
protective biofilms. In addition, even when 100% of the 
bacteria are killed by the antibiotic treatment, the persistence 
of the residual matrix of the biofilm can be a favorable soil 
for bacteria recolonization [8]. Therefore targeting the 
biofilm itself is crucial to reduce vaginosis recurrences. 
Several techniques used in our study, including the biofilm 
immobilization assay, demonstrated the interest of using 
lysozyme to fragilize and degrade G. vaginalis biofilms. We 
showed that recombinant human lysozyme could reduce both 
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Fig. 4. Anti-biofilm activity (crystal violet staining) of rhLys added during 24 h on 24-h biofilms produced by each of 
9 clinical strains of Gardnerella vaginalis. Statistically significant differences between conditions with and without 
lysozyme are represented as follows: **: P < 0.01, ***: P < 0.001; n = 4.
Table 1. Comparative activity spectrum of clindamycin and metronidazole administered during 24-h on 72-h biofilms generated by commensal and 
pathogenic vaginal strains
Species CTRL Clindamycin (µg/ml) Metronidazole (µg/ml)
0.1 10 100 0.1 10 600
Lactobacillus crispatus 20,000a 15,168 1,672 0 20,000a 20,000a 19,472
Lactobacillus gasseri 20,000a 67 0 0 20,000a 4,462 12,428
Lactobacillus jensenii 15 21 0 0 6,198 0 0
 Gardnerella vaginalis 15,216 153 0 0 5,516 7 0
Prevotella bivia 5 0 0 0 3,424 0 0
Peptostreptococcus tetradius 13,126 13,624 3,840 150 7,208 0 0
Escherichia coli 20,000a 20,000a 20,000a 20,000a 20,000a 20,000a 0
a20,000 CFUs is the counting limit. Therefore, it must be read as “at least 20,000 CFUs”.
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cohesion and biomass of pre-existing G. vaginalis biofilms 
and that it could also prevent biofilm formation. A recent 
study supports these findings [10].
In vivo vaginal biofilms may contain many species [22]. 
By using in vitro experiments, we modeled multi-species 
biofilms, each model originated by mixing G. vaginalis 
with one other microorganisms selected for its presence in 
pathological or non-pathological vagina. The biofilms so 
obtained were dependent on the species involved, and each 
of them was degraded by the recombinant human lysozyme
We also tested rhLys on clinical strains of G. vaginalis 
that presented great heterogeneity in biofilm production. The 
lysozyme degraded the biofilm produced by each clinical 
strain, its efficiency depending on the tested strain, which 
could be due to differences in the matrix constituting the 
biofilms.
We found that the biofilm produced by G. vaginalis was 
able to protect this species against clindamycin. Therefore, the 
combined use of an antibiotic (clindamycin or metronidazole) 
with rhLys was tested, and the bactericidal and biofilm 
degradation effects were greater than when lysozyme 
or antibiotic were tested alone. The comparison of both 
antibiotics regarding their toxicity against eukaryotic cells and 
on their spectrum of activity against vaginal species, revealed 
that metronidazole was a better choice than clindamycin. 
Regarding biofilm degradation, the increased destructive 
effect obtained when adding metronidazole to lysozyme 
might not only be due to the destruction of the existing 
biofilm but also to a lower production of new biofilm matrix 
due to the death of bacteria producing it. Co-administration 
of both molecules could therefore be highly recommended 
as a treatment of G. vaginalis-based vaginoses, helping not 
only to treat an isolated vaginosis but also to prevent recurrent 
vaginoses. A combined lysozyme-metronidazole toxicity test 
on epithelial would then be advisable as part of the treatment 
validation steps. 
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